By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celtaxsys, Inc. 

ATDC Biosciences Center
311 Ferst Drive
Atlanta  Georgia  30332  U.S.A.
Phone: 404-920-0700 Fax: 404-920-0701



Start Up

Company News
Celtaxsys, Inc. Has Regulatory Clearance To Begin Phase 2 Trial Of Oral CTX-4430 Anti-Inflammatory Therapy For Moderate To Severe Acne Vulgaris - Recruitment Of Patients To Commence Immediately 4/7/2015 12:32:05 PM
Celtaxsys, Inc. Lead Candidate Granted Orphan Designation In Cystic Fibrosis By FDA 2/3/2015 10:39:07 AM
Celtaxsys, Inc. Announces Sanjeev Ahuja As Chief Medical Officer 11/7/2014 8:23:24 AM
Celtaxsys, Inc. Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients 10/11/2013 9:02:03 AM
Celtaxsys, Inc. Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430 9/17/2013 8:30:32 AM
Celtaxsys, Inc. Restructures Management and Operations; CEO, CTO Out 9/10/2013 7:15:22 AM
Celtaxsys, Inc. Appoints Khalil Barrage to Board of Directors 4/19/2013 7:46:33 AM
Celtaxsys, Inc. Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation 1/3/2013 9:49:44 AM
Brett Premack, Ph.D. Joins Celtaxsys, Inc. as Chief Technology Officer 10/24/2012 8:50:19 AM
Celtaxsys, Inc. Acquires Clinical Stage Innate Immunity Drug for Inflammation 1/5/2012 3:01:59 PM